Opposite Roles of FAP-1 and Dynamin in the Regulation of Fas (CD95) Translocation to the Cell Surface and Susceptibility to Fas Ligand-mediated Apoptosis by Ivanov, Vladimir N. et al.
Opposite Roles of FAP-1 and Dynamin in the Regulation of
Fas (CD95) Translocation to the Cell Surface and
Susceptibility to Fas Ligand-mediated Apoptosis*
Received for publication, September 7, 2005, and in revised form, October 24, 2005 Published, JBC Papers in Press,November 23, 2005, DOI 10.1074/jbc.M509866200
Vladimir N. Ivanov‡1, Ze’ev Ronai§, and Tom K. Hei‡¶
From the ‡Center for Radiological Research, College of Physicians and Surgeons and the ¶Department of Environmental Health
Sciences, Mailman School of Public Health, Columbia University, New York, New York 10032 and the §Signal Transduction
Program, The Burnham Institute, La Jolla, California 92037
Humanmelanoma is themost aggressive form of skin cancer and
is extremely resistant to radiation and chemotherapy. One of the
critical parameters of this resistance is down-regulation of Fas
(CD95) cell-surface expression. Using TIG3 normal human fibro-
blasts and human melanoma cell lines, we investigated transcrip-
tional regulation of FAP-1, a regulator of Fas translocation in the
cell. Protein-tyrosine phosphatase FAP-1 (PTPN13, PTP-BAS)
interacts with human Fas protein and prevents its export from the
cytoplasm to the cell surface. In contrast, dynamin-2 facilitates Fas
protein translocation from the Golgi apparatus via the trans-Golgi
network to the cell surface. Suppression of dynamin functions by
dominant negative dynamin K44A blocks Fas export, whereas the
down-regulation of FAP-1 expression by specific RNA interference
restores Fas export (a phenomenon that could still be down-regu-
lated in the presence of dominant-negative dynamin). Based on the
FAP-1- and dynamin-dependent regulation of Fas translocation, we
have created humanmelanoma lines with different levels of surface
expression of Fas. Treatment of these melanoma lines with soluble
Fas ligand resulted in programmed cell death that was proportional
to the pre-existing levels of surface Fas. Taking into consideration
the well known observations that FAP-1 expression is often up-reg-
ulated in metastatic tumors, we have established a causal connec-
tion between high basal NF-B transcription factor activity (which
is a hallmark of many types of metastatic tumors) and NF-B-de-
pendent transcriptional regulation of FAP-1 gene expression that
finally restricts Fas protein trafficking, thereby, facilitating the sur-
vival of cancer cells.
The Fas receptor (synonyms: Apo-1, CD95, and TNFRSF6) is the
member of the TNF2 receptor superfamily, which contains signaling
molecules regulating programmed cell death. The interaction between
the Fas receptor and its ligand (FasL) initiates a complex pattern of
intracellular events involving the recruitment of specific adaptor pro-
tein and procaspase-8 to the receptor followed by activation of caspase
8, caspase 8-dependent stimulation of the downstream effector
caspases, and development of apoptosis (1, 2). The level of surface
expression of Fas is one of critical parameters in determining the ability
of cells to undergo apoptosis. Expression of Fas on the cell surface is a
multistage process that is regulated at different levels: (i) signaling path-
ways that target specific transcription factors are involved in the control
of Fas gene expression; (ii) the transcription of the Fas gene driven by
positive regulators (such as NF-B (3–5)) and by negative regulators
(such as AP-1 and Stat-3 (6)) in the context of general transcription
regulators (7); (iii) the translation of the FasmRNA, which is, by default,
dependent on the phosphatidylinositol 3-kinase-AKT-mammalian tar-
get of rapamycin signaling pathway (8); (iv) post-translational modifi-
cations (protein folding, glycosylation, and phosphorylation) accompa-
nying the maturation of Fas protein (9, 10); (v) Fas protein trafficking
from the cytoplasm to the cell surface (regulated by protein-protein
interactions, including FAP-1, a scaffolding protein (11–14); and (vi) Fas
receptor internalization and degradation.
Somatic mutagenesis of the Fas gene (15) and epigenetic regulatory
mechanismsmay affect the regulation of Fas expression or Fas-depend-
ent death signaling, both of which are suppressed in metastatic cancer
cells, often partially or almost completely (2, 16, 17). The general role of
the protein-tyrosine phosphatase FAP-1/PTP-Bas/PTPN13 in the neg-
ative regulation of Fas translocation among cancer cells has been previ-
ously described (11, 12). It is not surprising, however, that FAP-1 gene
expression itself is tightly regulated at the transcriptional level. In the
present study, based on the original observations demonstrating the
presence of the putative NF-B-binding elements in the promoter
region of the FAP-1 gene (18, 19), we have established a role of NF-B in
this regulation. Conversely, NF-B-dependent regulation of the Fas
gene is well established (3, 5). Simultaneous NF-B-dependent control
of the transcription of both the Fas receptor and its inhibitor, FAP-1
likely contributes to the heightened flexibility of the regulation of Fas
surface expression, thereby creating certain restrictions in its surface
expression level.
Additionally, there is a highly important phase of Fas protein traf-
ficking that occurs between the Golgi and the plasma membrane via
the trans-Golgi network. Recent investigations in this area have
established the critical role of dynamin-2 (Dyn-2) in the general
regulation of post-Golgi trafficking (20, 21). The particular questions
raised (which have been thoroughly investigated in the present
study) are linked with dynamin-dependent functions of Fas protein
trafficking, as well as with the functional interference between FAP-1
and dynamin in the regulation of the Fas protein export. Finally,
* This work was supported by National Institutes of Health Grant ES 11804, Superfund
Grant P42 ES 10349, and Environmental Center Grant P30 ES 09089. We have no
financial conflicts of interest. The costs of publication of this article were defrayed in
part by the payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: Center for Radiological Research,
Columbia University, VC11–204, 630 West 168th St., New York, NY 10032. Tel.: 212-
305-0846; Fax: 212-305-3229; E-mail: vni3@columbia.edu.
2 The abbreviations used are: TNF, tumor necrosis factor; TNFR, tumor necrosis factor
receptor; AP-1, activator protein 1; ATF2, activating transcription factor 2; ERK, extra-
cellular signal-regulated kinase; FAP-1, Fas associated phosphatase 1; GFP, green flu-
orescent protein; IB, inhibitor of NF-B; IKK, inhibitor nuclear factor B kinase; JNK,
Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase;
MFI,medium fluorescence intensity;NF-B, nuclear factorB; TRAIL, TNF-relatedapo-
ptosis-inducing ligand; FasL, Fas ligand; Dyn-2, dynamin-2; FACS, fluorescence-acti-
vated cell sorting; mAb, monoclonal antibody; CMV, cytomegalovirus; RNAi, RNA
interference; TGN, trans-Golgi network; BFA, BrefeldinA; STAT, signal transducers and
activators of transcription.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 3, pp. 1840–1852, January 20, 2006
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
1840 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 3•JANUARY 20, 2006
based on the FAP-1- and dynamin-dependent regulation of the Fas
export, we have established melanoma cell lines with the regulated
surface expression of the Fas receptor. The next critical issue
resolved by the present study is that the treatment of these Fas-
positive melanomas with soluble Fas ligand resulted in the pro-
grammed death of cancer cells, which was proportional to the pre-
existing surface Fas levels.
EXPERIMENTAL PROCEDURES
Materials—Sodium arsenite, cycloheximide, BrefeldinA, and tunica-
mycinwere obtained fromSigma; tumor necrosis factor- (TNF-) was
purchased from Roche Applied Science. Human soluble Fas ligand
(recombinant) and TRAIL (recombinant) were purchased from Alexis
(San Diego, CA); BD Cytofix/Cytoperm kit was obtained BD Pharmin-
gen; and pre-cast SDS-polyacrylamide gels were purchased from Bio-
Rad. EZ-Link Sulfo-NHS-LC-Biotin was obtained from Pierce. Strepta-
vidin-agarose was purchased from Invitrogen.
Cell Lines—Human melanoma cell lines LU1205 (also known as
1205lu), WM793, WM9 (22–25), and OM431 were maintained in a
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum, L-glutamine, and antibiotics. FEMXandHHMSXhuman
melanoma lines (26) were maintained in a RPMI1640 medium supple-
mented with 10% fetal calf serum and antibiotics. TIG3 human embry-
onic lung fibroblasts and HeLa human cervical carcinoma cells were
maintained in a Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, L-glutamine, and antibiotics.
FACSAnalysis of Fas Levels—Surface and total levels (“total”meaning
after cell permeabilization with BD Cytofix/Cytoperm) of Fas were
determined by staining with the correspondent phycoerythrin-conju-
gated anti-humanmAb and subsequent flow cytometry. Phycoerythrin-
conjugated mouse IgG1 was used as a monoclonal immunoglobulin
isotype control. A FACSCalibur flow cytometer (BD Biosciences) com-
bined with the CellQuest programwas used to perform flow cytometric
analysis with 40,000 cells for single color staining and with 80,000 cells
for double color staining. All experiments were independently repeated
four to five times.
Transfection and Luciferase Assay—The NF-B luciferase reporter
containing two B binding sites, Jun2-Luc reporter and empty vector
tk-Luc (27), were used to determine NF-B and AP-1 transactivation.
Additional reporter constructs used included: 1.7-kb FASpr-Luc (5)
and FAP1pr-Luc containing a 0.5-kb fragment of the proximal pro-
moter (19). Transient transfection of different reporter constructs (1
g) together with pCMV-gal (0.25 g) into 5  105 melanoma cells
was performed using Lipofectamine (Invitrogen). Proteins were pre-
pared for -galactosidase and luciferase analysis 16 h after transfection.
Luciferase activity was determined using the Luciferase assay system
(Promega, Madison, WI) and was normalized based on -galactosidase
levels.
In some experiments, using Lipofectamine (Invitrogen), mela-
noma cells were transfected with pEF-Fas-GFP expression con-
structs, either alone or in the presence of certain expression vectors,
including: pCMV-FAP1 and pCMV-FAP1CD (11); pcDNA3-
Dyn-1 and pcDNA3-Dyn-1 K44A (28, 29); pCMV4-Dyn-2,
pCMV4-Dyn-2 K44A, and pCMV4-Dyn-2 Y231F/Y597F (30);
pcDNA3-IKKS178E/S181E (31); and MEKK1 expression vector
(32), as well as pCMV-Gal. 8–30 h after transfection, GFP-positive
cells were stained with phycoerythrin-anti Fas monoclonal antibody
(mAb) (BD Pharmingen) to determine surface Fas expression by flow
cytometry. Two parameters: 1) the percentage of Fas GFP cells
among GFP cells and 2) the mean fluorescence intensity (MFI) of
surface Fas levels were used to evaluate the efficiency of surface
Fas-GFP translocation. Flow cytometry was performed using a FAC-
SCalibur flow cytometer (BD Biosciences) in conjunction with the
CellQuest program. The specific activity of -galactosidase was used
for the normalization of the efficiency of transfection. Tet-off HeLa
system expressing mutant, dynamin-1 K44A (33), was kindly pro-
vided by Dr. S. L. Schmid (The Scripps Research Institute, La Jolla,
CA).
Treatment and Apoptosis Studies—Cells were exposed to soluble
FasL (50 ng/ml) in combination with cycloheximide (1 g/ml). Apop-
tosis was then assessed by quantifying the percentage of hypodiploid
nuclei undergoing DNA fragmentation (34). Flow cytometric analysis
was performed on a FACSCalibur flow cytometer.
FAP-1 Suppression by RNAi—The pSUPER retro (pRS) RNA inter-
ference (RNAi) system (Oligoengine, Seattle, WA), which has been uti-
lized for the production of small RNAi transcripts used to suppress
FAP-1 expression, was previously described (11).
Western Blot Analysis and Immunoprecipitation—Total cell lysates
(50–100g of protein) were resolved on 10% SDS-PAGE and processed
according to standard protocols. The antibodies used forWestern blot-
ting included monoclonal anti--Actin (Sigma); monoclonal anti-dy-
namin-1 and anti-dynamin-2 (Upstate, Lake Placid, NY); monoclonal
anti-human Fas (G254–274). Polyclonal anti-FAP-1 antibody was
kindly provided by T. A. Sato (Columbia University, NY). Optimal dilu-
tions of primary Abs were 1:1,000 to 1:10,000. The secondary Abs (anti-
rabbit or anti-mouse) were conjugated to horseradish peroxidase (dilu-
tion 1:5,000 to 1:10,000); signals were detected using the ECL system
(Amersham Biosciences).
Total levels of Fas were determined by using the immunoprecipita-
tion of total cell extracts with anti-human Fas mAb and G-protein-
Sepharose beads (Sigma) combined with subsequent Western analysis.
Fas-GFP-fused protein was immunoprecipitated either with anti-Fas or
anti-GFP Abs, with subsequent Western analysis using anti-Fas mAb.
Cell-surface Labeling with Biotin—Biotinylation of cell-surface pro-
teins was performed using EZ-Link Sulfo-NHS-LC-Biotin (Pierce)
according to the manufacturer’s instruction. Cell proteins were dis-
solved using 1% Triton X-100, 0.14 MNaCl, 10 mMTris-HCl (pH 7.5), 2
mM leupeptin, 2 mM aprotinin, 1 mM phenylmethylsulfonyl fluoride.
Biotinylated proteins were precipitated using Streptavidin-agarose
beads, dissolved in sample buffer, and subjected to SDS-gel electro-
phoresis followed by Western blot analysis with anti-Fas Ab.
Electrophoretic Mobility Shift Assay—Electrophoretic mobility shift
assay was performed for the detection of NF-B DNA-binding activity
as previously described (35), using the labeled double strand oligonu-
cleotide AGCTTGGGGACTTTCCAGCCG. (Binding sites are under-
lined.) Ubiquitous NF-Y DNA-binding activity was used as an internal
control (35).
RESULTS
Fas Receptor Translocation to the Cell Surface—We and others have
previously observed that some cancer cell lines, such as human ocular
melanoma OM431 and human metastatic melanomas LU1205 and
HHMSX, contained a substantial cytoplasmic pool of Fas in complex
with a scatter protein FAP-1 (11, 12). TIG3 human embryonic lung
fibroblasts express moderate levels of FAP-1, which interacts with
endogenous cytoplasmic Fas, as shown by the coimmunoprecipitation
of FAP-1 and Fas gp54 (Fig. 1A). Alternatively, most of the Fas receptor
is located on the cell surface of FEMX cells (11) due to very low level of
expression of the FAP-1 protein in these cells (Fig. 1A).
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FIGURE 1. Fas translocation to the cell surface: the negative effects of tunicamycin, BFA, and FAP-1 overexpression. A, Western blot analysis of protein levels of Fas (a mature
glycoprotein of 54 kDa and partially glycosylated protein of 45 kDa) in FEMX human melanoma cells and in TIG3 human embryonic lung fibroblasts; -actin was used as a protein
downloading control; immunoprecipitationwith anti-FAP-1 Ab and the subsequentWestern analysiswith anti-FasmAbor anti-FAP-1 Abdemonstrate FAP-1/Fas protein association
in TIG3 cells: FAP-1 (270 kDa), Fas (gp54); ns, nonspecific band. B, FEMXor TIG3 cells were non-treated or treatedwith tunicamycin (Tun) or Brefeldin A (BFA) for 16 h; surface Fas levels
were determined using cell stainingwith anti-Fas-PEmAb and subsequent flow cytometry. Error bars representmean S.D. from three independent experiments. C, directWestern
analysiswas performed for determination of FAP-1 levels after transfection of TIG3 cellswith FAP-1 expression construct; immunoprecipitationwith the subsequentWestern analysis
was performed todetermine Fas-GFP levels in TIG3 cells, whichwere transiently transfectedwith pEF-Fas-GFPwt in thepresence or in the absence of FAP-1 expression vector.D, TIG3
cells were transfectedwith pEF-Fas-GFP and the empty vector pCMV4 (1:1) or with pEF-Fas-GFP and FAP-1 expression constructs (1:1); 24 h after transfection, cells were stainedwith
anti-Fas-PEmAbandanalyzed for surface Fas expressionby flowcytometry;MFI of surface Fas levels andpercentageof the FasGFP andFasGFP cells are indicated; thebrightest
Fas cells were gated as the ‘H ’ rectangular. Gating of unstained cells, single-stained with anti-Fas-PE mAb cells and GFP-positive cells is indicated. E, surface Fas expression was
detected in transfected TIG3 cells by biotinylation of cell-surface proteins with subsequent precipitation of biotinylated proteins by Streptavidin-agarose beads and identification of
surface proteins using immunoblotting and anti-Fas Ab. Fas-GFP fused protein (75 kDa) was detected on the cell surface after transfection of Fas-GFP; cotransfection with FAP-1
expression construct down-regulated Fas-GFP surface levels.
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We decided to use TIG3 cells as a model to study Fas trafficking due
to the high transfection efficiency of these cells compared with most
melanomas. In general, Fas protein translocation occurs in the cells
using the conventional rules of protein receptor export to cell surface,
showing dependence of corresponding post-translationalmodifications
(glycosylation and phosphorylation), protein-protein interactions, and
the integrity of theGolgi apparatus and the trans-Golgi network (TGN).
As expected, brefeldinA (BFA, 100 ng/ml), an inhibitor of protein trans-
location from the endoplasmatic reticulum to the Golgi, and tunicamy-
cin (5 g/ml), a general inhibitor of protein N-glycosylation, notably
suppressed endogenous surface expression of Fas in Fas-positive mela-
nomas, including FEMX cells, 16 h after treatment (Fig. 1B). The effects
of these agents on the surface expression of endogenous Fas in TIG3
cells were less pronounced due to the low basal levels of surface Fas
expression on these cells.
Based on our previous observations (11), we transfected TIG3 cells
with the pEF-Fas-GFP expression construct, which resulted in a high
expression of surface Fas-GFP-fused protein. As expected, surface Fas
expression was down-regulated after the cotransfection of Fas-GFP
with FAP-1 expression vector (Fig. 1, C and D) due to a substantial
deletion of the bright Fas-positive cells gated as the ‘H ’ rectangular in
Fig. 1D. MFI, which determines levels of surface Fas expression, has
been dramatically decreased, whereas total percentage of GFP cells
was similar following cotransfection either with the empty vector or
FAP-1 expression vector (Fig. 1D). This reflects a substantial retardation
of Fas-GFP translocation in cells with FAP-1 overexpression. These
results obtained with TIG3 cells are very similar to our previous obser-
vations on several melanoma cell lines (11). Furthermore, biotinylation
of the cell-surface proteins, their subsequent precipitationwith Strepta-
vidin-agarose, and immunoblotting with anti-Fas Ab detected Fas-
GFP-fused protein on the cell surface. Cotransfection with FAP-1
expression vector substantially reduced Fas-GFP surface levels (Fig. 1E).
As we previously demonstrated, the transfection of FEMXmelanoma
cells with pEF-Fas-GFP expression construct resulted in an appearance
of fused Fas-GFP protein in the Golgi 8 h after transfection, followed by
translocation of Fas-GFP via TGN to the cell surface 30 h after trans-
fection (11). Tunicamycin (Fig. 2) and BFA notably suppressed the traf-
ficking of exogenous Fas-GFP protein in FEMX cells. Transfected
FEMX cells with high levels of Fas-GFP expression on the cell surface
acquired a high sensitivity to FasL-mediated death (11), whereas tuni-
camycin or BFA pretreatment partially suppressed this susceptibility.
Conversely, N102P and N120P mutations in the glycosylation sites of
Fas protein (36) have differentially affected Fas-GFP translocation to the
cell surface: N102P mutation had strong negative effects on Fas-GFP
export in all tested lines, whereas levels of surface expression of Fas
N120P differed greatly in distinct lines (data not shown). In TIG3 cells,
Fas (N120P)-GFP-mutated protein can be detected, although at low
levels in total cell extracts following immunoprecipitation; surface
expression of this protein was very low (data not shown). Equal effi-
ciency of transfection was proofed in these experiments by co-transfec-
tion of Fas expression constructs with pCMV--gal and determination
of -galactosidase activity.
Transcriptional Regulation of FAP-1 Gene Expression: A Role of
NF-B—Because FAP-1 is a central negative regulator of Fas trafficking
in human cells, it would be important to determine the mechanism
behind the transcriptional control of endogenous FAP-1 gene expres-
sion. Furthermore, many human tumors possess high levels of expres-
sion of FAP-1 (synonyms: PTPN13, PTP-BAS, PTPL1, and hPTP1E)
(37), including ovarian carcinomas (38), melanomas (11), pancreatic
cancers (12), Ewing’s sarcomas (39), and colon adenocarcinomas (40).
Additionally, numerous metastatic tumors are characterized by high
basal NF-B activity (41–43), which is (inmany cases) a hallmark of the
advanced stages of the cancer development. NF-B has potential bind-
ing sites in the FAP-1 promoters (Fig. 3A) (19). This was a reason to
determine whether this transcription factor is involved directly or indi-
rectly in the regulation of FAP-1 expression. To address this question,
we used TIG3 human embryonic fibroblasts as a model in our initial
experiments. We have transfected TIG3 cells either by the empty vec-
tor, pCMV4, or by an expression construct encoding super-stable
IBN (44). 24 h after transfection, a dramatic accumulation of super-
stable IBN was accompanied by a down-regulation of both NF-B
DNA-binding activity (p65-p50) and FAP-1 mRNA with protein levels
(Fig. 3, B–D). A notable decrease in NF-B activity (Fig. 3F), FAP-1
mRNA, and protein levels (data not shown)was also detected in LU1205
melanoma cells, following the transfection of super-stable IBN.
Cotransfection of Fas-GFP expression construct together with IBN
construct (which successfully blocked endogenous FAP-1 expression)
resulted in both the substantial increase of Fas-GFP translocation to the
cell surface in TIG3 fibroblasts (Fig. 3E) and a notable increase in
LU1205 melanoma cells (Fig. 3G). These observations were based on
FIGURE 2. Fas-GFP-fused protein translocation to the cell surface in FEMX: the neg-
ative effects of tunicamycin. FEMXmelanoma cells were transiently transfectedwith a
pEF-Fas-GFP expression construct and analyzed 8, 20, and 30 h after transfection; some
cell cultures were treatedwith tunicamycin for 12 h. Confocal analysis of Fas-GFP (green)
and aGolgimarker -adaptin (red; secondary Ab labeledwith Texas Red)was performed
for the determination of subcellular localization.
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FACS analysis of transfected cells, which were stained with anti-Fas-PE
mAb for detection of surface Fas levels. A subpopulation of TIG3 cells
with a low surface expression of Fas-GFP had nearly disappeared after
transfection with IBN (accompanied by the up-regulation of total
MFI of surface Fas). Such changeswere less pronounced in LU1205 cells
due to a less effective transfection of these cells (compare levels of inhi-
bition of p65-p50 DNA binding activity shown in Fig. 3 (D and F)). In
general, these data have indicated that a negative regulation of the
endogenous levels of FAP-1 by IBN was accompanied by positive
effects on Fas-GFP translocation to the cell surface.
To further determine the role of NF-B in the regulation of FAP-1
gene expression, we performed transfection and overexpression of per-
manently active IB kinase, IKK S178E/S181E, or MEKK1 (both
kinases are effective activators of NF-B (31, 45), and MEKK1, which
is an upstream activator of the IKK complex, also activates the MAPK
pathways) in TIG3 cells. This procedure induced the up-regulation of
the NF-B p65-p50 DNA-binding activity as well as endogenous FAP-1
levels (Fig. 4A). To determine whether NF-B directly regulates FAP-1
promoter activity, the proximal promoter (a 0.5-kb fragment starting
near ATG1) was cloned in a pGL3-basic reporter (19). The promoter
activity was analyzed using a standard luciferase assay, which showed a
relatively small increase (2-fold) of the basic reporter activity driven by
the cloned promoter; furthermore, the reporter activity was notably
up-regulated by IKK orMEKK1 expression constructs (producing an
additional 2-fold increase). However, this increase was abolished by the
mutation of the NF-B site in the FAP-1 region (Fig. 4B). Our data
FIGURE 3. Super-stable inhibitor IBN down-regulates FAP-1 expression and up-regulates surface Fas-GFP expression. A, putative NF-B-binding elements in the FAP-1
gene regulatory region are indicated. B, TIG3 cells were transfected by the empty vector pCMV4 or by expression construct encoding super-stable IBN; corresponding changes
in the endogenous FAP-1 mRNA levels following transfection of IBN were determined with RT-PCR; normalization was based on glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) levels. C, Western blot analysis of overexpressed IBN (detected with Ab against C-terminal IB) and of endogenous FAP-1 levels has been performed 24 h after
transfection; actin was used as a protein loading control. D, NF-B p65-p50 DNA-binding activity (determined by electrophoretic mobility shift assay) was substantially suppressed
in the presence of overexpressed IBN (FP, free oligonucleotide probe). E, cotransfection of Fas-GFP expression constructwith IBNexpression construct (which blocked FAP-1
expression) resulted in the notable increase of Fas-GFP translocation to the surface of TIG3 cells that was determined by staining TIG3 cells with anti-Fas-PEmAb and the subsequent
flow cytometry; ‘High ’ and ‘Low ’ indicate positions of the cell subpopulationswith high and low levels of surface expression of Fas receptor; MFI values (S.D. of parallel repeats) are
indicated. Results of typical experiment from three independent experiments are presented. F, NF-B p65-p50 DNA-binding activity (determined by electrophoretic mobility shift
assay) was partially suppressed in the presence of overexpressed IBN in LU1205 cells (FP, free oligonucleotide probe). G, cotransfection of Fas-GFP expression construct with
IBN expression construct resulted in the notable increase of Fas-GFP translocation to the surface of LU1205 cells that was determined by staining LU1205 cells with anti-Fas-PE
mAb and subsequent flow cytometry. Data of one typical experiment (from three independent experiments) are presented.
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demonstrated that the NF-B-dependent up-regulation of FAP-1 pro-
tein was primarily dependent on the promoter activity. This resulted in
the down-regulation of Fas-GFP translocation (determined by FACS
analysis), because the percentage of cells with high surface Fas levels
notably decreased after transfectionwith theNF-B activators (Fig. 4C).
Taken together with the experiments on negative regulation of FAP-1
expression by IBN, these results undoubtedly demonstrate a role of
NF-B in the FAP-1 gene transcriptional regulation. Furthermore,
NF-B-mediated up-regulation of FAP-1 levels may quite possibly be a
special mechanism that could restrict Fas surface levels in advanced
cancers. To determine any additional FAP-1-independent NF-B-de-
pendent effects on signaling pathways controlling Fas trafficking, we
transfected TIG3 cells with pEF-Fas-GFP in the presence of pCMV-
IBN or pCMV-FAP-1 alone or both in combination. IBN ex-
pression did not change the negative effects of FAP-1 on Fas-GFP
translocation (Fig. 4D), excluding a role for an FAP-1-independent,
NF-B-dependent pathway in Fas trafficking.
Opposite Roles of Dynamin and FAP-1 in the Regulation of Fas
Translocation—The subsequent events of Fas protein trafficking in
the cell include translocation from the endoplasmic reticulum to the
Golgi, and then to the plasma membrane via the TGN. The general
role of the large GTPase dynamin-2 (Dyn-2) in the post-Golgi traf-
ficking has been previously postulated (20, 21). Dynamin-2 is a ubiq-
uitous protein, whereas dynamin-1 is more characteristic for cells of
the nervous system; however, both dynamins are implicated in the
regulation of clathrin-mediated endocytosis (46, 47). It was also
shown that either Dyn-1 K44A- or Dyn-2 K44A-mutated proteins
might serve as a dominant-negative regulator of functions for both
dynamin-1 and dynamin-2 (48). Based on these general consider-
ations, using immunoprecipitation and subsequent Western analy-
sis, we have determined the expression levels of both forms of
dynamin in TIG3 fibroblasts, as well as in several lines of human
melanomas. HeLa Tet-off cell system (which produced Dyn-1) has
been used as a positive control (48) (Fig. 5A). Interestingly, TIG3
FIGURE4.NF-Bactivationby IKKorMEKK1up-regulatesFAP-1expression.A, transfectionandoverexpressionof IKKS178E/S181EorMEKK1 in TIG3 cells up-regulated the
NF-BDNA-binding activity and increased endogenous FAP-1 levels; non-inducible NF-Y DNA-binding activity served as loading control. B, regulation of pFAP1-Luc reporter activity
by inhibitor and activators of the NF-B activity; the FAP-1 gene intron 1 contains several putative binding sites for transcription factors, including SP-1, NF-B, AP-1, and STATs; a
0.5-kb fragment of this region was cloned in the pGL3-basic reporter; a standard luciferase reporter assay was performed for wild-type or NF-B-mutated reporter constructs in the
presence of indicated regulators of NF-B activity. C, NF-B-dependent down-regulation of Fas-GFP translocation has been determined by FACS analysis; the percentages of gated
cells in the regionswith high and low Fas surface expression and their MFI are indicated. Error bars representmean S.D. from three independent experiments.D, overexpression of
IBN did not affect exogenous FAP1-dependent down-regulation of Fas-GFP translocation. TIG3 cells were transfected with pEF-Fas-GFP together with four different combina-
tions of expression constructs: pCMV4 (vector), pCMV4-IBN plus pCMV4, pCMV4-FAP1 plus pCMV4, and pCMV4-FAP1 plus pCMV4-IBN. Surface Fas expression has been
determined by FACS analysis using anti-Fas-PE mAb. Error bars represent mean S.D. from three independent experiments.
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cells contain both dynamins at relatively low levels. Some melanoma
lines contain mostly Dyn-1 (WM793, WM9, and OM431 cells) or
both Dyn-1 and Dyn-2 (LU1205 cells); finally FEMX cells contain, as
a rule, only Dyn-2. We were unable to demonstrate a direct protein-
protein interaction between dynamins and Fas, or dynamins and
FAP-1 using immunoprecipitation followed by Western blot analy-
sis, although we cannot exclude a possibility of such interactions.
To investigate the effects of dominant-negative dynamin on the
endogenous surface Fas levels, we first used the HeLa Tet-off system
combined with the inducible production of dominant-negative
Dyn-1 K44A (48) (Fig. 5B). Dyn-1 K44A induction by tetracycline
withdrawal was accompanied by a pronounced down-regulation of
the endogenous Fas expression on the cell surface (decrease in MFI
from 30 to 13) (Fig. 5C). Hence, dynamin (probably, the ubiquitous
dynamin-2, which is present at high levels in HeLa; see Fig. 5A) plays
a positive regulatory role in Fas trafficking. Furthermore, transient
transfection of TIG3 cells with Dyn-1 K44A was accompanied by
decreasing endogenous levels of surface Fas expression (data not
shown).
To successfully elucidate functional interference between FAP-1 and
dynamins in the regulation of Fas export, TIG3 cells have been trans-
fected by the Fas-GFP expression vector in combination with either
dominant-negative Dyn-1K44A (which suppressed function of both
dynamins) or FAP-1 RNAi expression construct. Some TIG3 cells were
transfected by FAS-GFP and both Dyn1K44A and FAP-1 RNAi (Fig.
6A). Surface expression of Fas-GFP was determined by staining with
FIGURE 5. Dominant-negative dynamin-1 K44A
down-regulates Fas surface expression. A, lev-
els of endogenous dynamin-1 (Dyn-1) or
dynamin-2 (Dyn-2) in the indicated cell lines were
determined using immunoprecipitationwith anti-
Dyn-1 or anti-Dyn-2 mAbs followed by Western
blot analysis with the same mAbs; human mela-
noma lines, TIG3 fibroblasts and HeLa cells with
Tet-off control of Dyn-1 K44A expression were
used. B and C, HeLa Tet-off system for controlled
expression of Dyn-1 K44A has been used; overex-
pression of Dyn-1 K44A (24 h after tetracycline
withdrawn) has resulted in down-regulation of
endogenous surface Fas receptor expression,
whichwasdeterminedby FACS analysis. Results of
typical experiment from four independent exper-
iments are presented.
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FIGURE 6. Functional interaction of FAP-1 and dynamin regulates Fas-GFP surface levels in TIG3 cells. A, TIG3 cells were transfected by empty vector pRS, combinations of
pRS-FAP-1RNAiwithDyn-1K44Aor control RNAiwithDyn-1K44A;Westernblot analysiswasperformed for detection FAP-1 andDyn-1K44A levels 48hafter transfection.B, TIG3 cells
were transiently transfected with the empty vector pcDNA3 or with the expression construct encoding dominant-negative FAP-1CD in the presence of Fas-GFP expression vector;
levels of Fas-GFP were determined by IP/W, whereas levels of (FAP-1 plus FAP1CD) were determined by direct Western analysis 48 h after transfection. C and D, TIG3 cells were
transfected with Fas-GFP in the indicated combinations of the empty vector, FAP-1 RNAi, control RNAi, Dyn-1 K44A, and FAP1-DN (FAP-1CD). FACS analysis of TIG3 cells was
performed 48 h after transfection, and cells were stained with anti-Fas-PE mAb and analyzed by the flow cytometry. Results of one typical experiment (C) and of three independent
experiments (D) are presented. Error bars represent mean S.D. from three independent experiments.
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anti-Fas-PE mAb and flow cytometry. Dyn-1 K44A effectively
decreased levels of Fas surface expression (MFI dropped almost 2-fold
after 48 h); in contrast, FAP-1 RNAi (by inhibiting FAP-1) increased
these levels: from 1100 to 1700 MFI. Finally, a triple transfection of
Fas-GFP together with Dyn-1 K44A and FAP-1 RNAi still caused the
down-regulation of surface Fas levels, indicating that dynamin is criti-
cally important for the Fas export and operates downstream of FAP-1
(Fig. 6, C and D). Similar results have been obtained when we used
FAP-1CD dominant-negative construct (for the effective suppression
of FAP-1 function) and dominant-negative Dyn-1K44A (Fig. 6, B and
D).Once again, FAP-1CDandDyn-1K44Ahad opposite effects on the
Fas-GFP export; however, the combined treatment still resulted in the
down-regulation of Fas translocation to the cell surface (Fig. 6D). Taken
together, these data indicate that the suppression of the function of
dynamin remains an effective method of blocking Fas export in the cell,
despite releasing Fas from FAP-1 interaction.
FIGURE 7. Regulation of surface Fas expression
and susceptibility to the Fas-mediated apopto-
sis by dynamin and FAP1 in melanoma cells. A,
LU1205 melanoma cells were stably transfected
with either Dyn-1 K44A or FAP1 RNAi expression
constructs; surface Fas expression in transfected
cell lines was determined by FACS analysis; MFI is
indicated. B, Western blot analysis of Dyn-1 and
FAP1 levels in transfected LU1205 cells. C, apopto-
sis was induced by soluble FasL (50–100 ng/ml)
and cycloheximide (1 g/ml) treatment for 18 h;
apoptosis levels were determined using pro-
pidium iodide staining of DNA and the flow
cytometry. Error bars represent mean S.D. from
three independent experiments.D and E, Fas-GFP-
fused protein translocation to the cell surface in
HHMSX cells. HHMSX melanoma cells were tran-
siently transfected with a pEF-Fas-GFP and FAP-1
RNAi or pEF-Fas-GFP and control RNAi constructs
and analyzed 40 h after transfection. Surface Fas
expression was determined by using anti-Fas-PE
mAb and FACS analysis (D). Confocal analysis of
Fas-GFP-fused protein (green) and surface Fas
expression (red; using primary anti-Fas mAb and
secondary Ab labeled with Texas Red) was per-
formed for the determination of subcellular local-
ization (E).
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Regulation of Surface Fas Levels and FasL-mediated Apoptosis in
Melanoma—To find physiological consequences of the Fas export
regulation by dynamin, we established LU1205 human melanoma
cell lines (mass cultures) that have been stably transfected either
with dominant-negative Dyn-1 K44A or Dyn-2 K44A; LU1205 cells
stably transfected with the FAP-1 RNAi construct have been also
generated. Melanoma cells transfected with Dyn-1 K44A showed a
decrease, whereas those transfected with FAP1-RNAi (which effec-
tively down-regulated FAP-1 levels) showed an up-regulation of
endogenous surface Fas expression (Fig. 7, A and B). Established
LU1205 melanoma lines responded to recombinant FasL (50 ng/ml
and 100 ng/ml, respectively) and cycloheximide (1 g/ml) treatment
by the induction of apoptosis, which was proportional to pre-exist-
ing Fas levels (Fig. 7C).
Highly aggressive HHMSX human melanoma cells have very low
Fas cell-surface expression and, consequently, were convenient for
studying the regulation of Fas export. We observed previously that
transfected Fas-GFP was maintained in the cytoplasm of HHMSX
melanoma cells due to interaction with endogenous FAP-1. Tran-
sient cotransfection of these cells with Fas-GFP and FAP-1-RNAi
(2:1) resulted in Fas translocation to the cell surface detected by
FACS analysis 40 h after transfection (Fig. 7D). Furthermore,
20–30% of GFP-positive cells became surface Fas-positive, as was
demonstrated by microscopy using anti-Fas mAb and the secondary
Ab labeled with Texas Red (Fig. 7E).
Dyn-2 K44A affects Fas expression in a way very similar to that of
Dyn-1 K44A; double mutant Dyn-2 Y231F/Y597F was less effective
for down-regulation of surface Fas expression (Fig. 8A). These
results provide further evidence of a regulatory role of dynamins in
the Golgi/TGN-mediated Fas export to the cell surface. As expected,
dynamin-2 plays a more universal role in the regulation of death
receptor translocation to the cell surface. Indeed, LU1205 cells stably
transfected with either Dyn-2 K44A or Dyn-2 Y231F/Y597F demon-
strated negative regulation of surface expression of both death
FIGURE 8.Regulation of surface Fas expression and susceptibility to the Fas- and TRAIL-R1-mediated apoptosis by dynamin-2 inmelanoma cells. A, LU1205melanoma cells
were stably transfected with either the empty vector pCMV4 or Dyn-2 K44A or Dyn-2 Y231F/Y597F expression constructs; surface Fas expression in transfected cell lines was
determined by FACS analysis; MFI is indicated. B, Western blot analysis of Dyn-2 levels in indicated transfected cell lines using anti-Dyn-2 mAb. C, surface TRAIL-R1 expression in
transfected cell lines was determined by FACS analysis; MFI is indicated. D, apoptosis levels were determined 18 h after treatments with recombinant FasL (25–100 ng/ml) and
recombinant TRAIL (50–100 ng/ml) together with cycloheximide (CHX, 1 g/ml) using propidium iodide-staining DNA and flow cytometry. Error bars represent mean S.D. from
three independent experiments.
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receptors, Fas and TRAIL-R1, even when the basal levels of surface
TRAIL-R1 were relatively low (Fig. 8 A-C). Treatment of established
melanoma lines with recombinant FasL (25–100 ng/ml) or TRAIL
(50–100 ng/ml, in combination with cycloheximide, 1 g/ml)
induced apoptosis, which was proportional to the surface level of the
correspondent receptor. Negative effects of dominant-negative
Dyn-2 on apoptosis were observed for both types of treatments (Fig.
8D). Taken together, these data demonstrated a supplementary level
of regulation in surface expression of Fas receptor by dynamin,
which could change a susceptibility of cancer cells to apoptosis; and,
therefore, may be critically important for a future development of
effective anti-cancer treatment.
Note that we can exclude the possibility that effects of dominant-
negative dynamin K44A on Fas surface expression are based on the
inhibition of endocytosis (rather than post-Golgi trafficking). This can
be derived from the observation that phenylarsine oxide, an inhibitor of
endocytosis (49), has stabilized and up-regulated surface levels of Fas
(data not shown) in contrast to the effects of dominant-negative
dynamin that have effectively decreased these levels.
DISCUSSION
Suppressed apoptotic signaling is a characteristic feature of advanced
stages of cancer development that are driven by specific genetic and
epigenetic mechanisms, including the down-regulation of surface
expression of Fas death receptor (2, 15–17). The ambitious purpose of
the numerous studies of anti-cancer treatment is to specifically up-reg-
ulate the susceptibility of cancer cells for the induction of apoptosis via
restoration of surface expression of Fas death receptor and/or Fas-me-
diated signaling. Alternatively, an important acquired feature of
advanced tumors is either the production of active FasL or, at least, the
sequestering FasL in the cytoplasmic pools (50), which, in general, may
facilitate restriction of anti-tumor immune response (51). However, the
positive aspect of this is that the simultaneous induction of expression of
Fas receptor and its ligand may create conditions for programmed sui-
cide of cancer cells (52, 53).
In our present study, we are currently engaged in the investigation of
Fas receptor export to the cell surface. Opposite roles of FAP-1 as an
inhibitor of Fas export, and dynamins as general activators, allow us to
quite precisely regulate levels of Fas expression on the cell surface.
Dominant negative Dyn-1 K44A was shown to effectively suppress
functions of both main dynamins, Dyn-1 and Dyn-2 (48). Dyn-2 K44A
has demonstrated very similar effects in transfected LU1205 melanoma
cells, which express both Dyn-1 and Dyn-2 (see Fig. 5A). An additional
study, which could precisely distinguish the effects of the particular
dynamins in the regulation of Fas trafficking in human melanomas,
would be necessary.
A specific known function of protein-tyrosine phosphatase FAP-
1/PTPL1/PTP-BL is probably the regulation of insulin-induced sig-
naling through the dephosphorylation of insulin growth factor
receptor (54). Furthermore, FAP-1 may play the role of a scaffolding
FIGURE 9. The Fas cycle in the cell: the role of
NF-B in the regulation of the total and surface
Fas expression.NF-Bplays a dual role in the reg-
ulation of the surface Fas expression by control-
ling transcription of both genes: Fas and a sup-
pressor of Fas protein export, FAP-1. Both genes
contain the NF-B-binding sites in their promot-
ers. Dynamin-2 facilitates Fas translocation from
the Golgi and TGN to cell surface. Finally, FasL/Fas
interaction, in addition to the canonical induction
of death signaling, may induce the NF-B signal-
ingpathway, up-regulating FAP-1geneexpression
with subsequent restriction of the Fas export to
the cell surface. (See an additional description of
this figure under “Discussion.”)
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protein, at least, for two protein targets: Fas and the zyxin-related
protein, TRIP6 (55). Note that the nuclear form of TRIP6 is a coac-
tivator of NF-B-dependent gene expression (56). Results of the cur-
rent study demonstrate a critical role of transcription factor NF-B
in the regulation of FAP-1 gene expression. Taken together, these
data indicate a potentially effective mechanism behind the regula-
tion of the Fas export in the cells directed by the regulation of NF-B
signaling (Fig. 9). A critical feature of this regulation is the existence
of, at least, two interfering processes: the NF-B-dependent tran-
scription of Fas gene and the NF-B-dependent transcription of
FAP-1 gene encoding a Fas-scaffolding protein. Both genes contain
several NF-B-binding sites in the gene promoters. NF-B-mediated
expression of FAP-1 protein may be a specific mechanism that could
restrict Fas surface levels in advanced cancers. Both NF-B and its
coactivator, TRIP6, are present in their non-active forms within the
cytoplasm, in the complexes with IB (57) and FAP-1 (55), respec-
tively. These factors (NF-B and TRIP6) could be translocated into
the nucleus upon signal-dependent activation. Conversely, FAP-1
can bind Fas protein with suppression of its trafficking to the cell
surface, while dynamin-2, as a general regulator of post-Golgi traf-
ficking (20), facilitates Fas translocation. The emerging picture of the
regulation of surface Fas expression becomes even more compli-
cated, because FasL/Fas interaction may cause, especially in cancer
cells, the induction of the NF-B-activating signals (15) additionally
to the main TNF/TNFR1,2-mediated NF-B signaling pathway
(57). This may provide a supplementary feedback mechanism for
restriction of Fas protein export via FAP-1 expression. Finally, endo-
cytosis, sorting, and degradation of the Fas receptor are also involved
in the regulation of its surface expression (58, 59).
Furthermore, it was quite obvious that NF-B was not the only tran-
scription factor involved in FAP-1 regulation. For example, the onco-
genic transcription factor, EWS-FL11, has been recently implicated in
control of FAP-1 transcription in Erwing sarcoma (39). Our preliminary
experiments have also indicated a negative role of c-Jun (but not of
Stat3) in the regulation of the FAP-1 proximal promoter activity (data
not shown).
One of the important results of the present study was the generation
ofmelanoma cells with increased surface expression of the Fas receptor,
based on the suppression of FAP-1 expression by a specific RNAi. A
subsequent treatment of these cells with soluble FasL resulted in the
induction of apoptosis of these cancer cells. Furthermore, induced sur-
face expression of the endogenous Fas Ligand in these Fas-positivemel-
anomas was also accompanied by massive cell death.3
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